Skip to main content

Table 2 Modulation of costimulatory and coregulatory molecule expression by iv-SIL

From: Immunomodulating effects of the anti-viral agent Silibinin in liver transplant patients with HCV recurrence

% (mean ± SD) pDC   mDC  
  Pre Post p Pre Post p
HLA-DR 92.9 ± 5.5 90.9 ± 7.8 0.1600 93.7 ± 9.7 87.5 ± 17.3 0.1035
CD83 45.9 ± 16.2 50.3 ± 20.6 0.6231 26.7 ± 10.7 37.7 ± 23.1 0.1793
CD86 59.8 ± 14.2 65.6 ± 10.9 0.2250 90.6 ± 5.3 87.8 ± 14.0 0.6306
ICOSL 45.1 ± 18.3 52.2 ± 12.3 0.2758 29.6 ± 12.6 36.2 ± 7.2 0.0122
PD-L1 18.9 ± 11.2 25.5 ± 12.0 0.0883 10.6 ± 6.8 17.0 ± 10.6 0.0938
HLA-G 26.2 ± 8.1 36.19 ± 8.6 0.0449 45.8 ± 10.3 50.8 ± 11.6 0.3614
IL-T4 97.3 ± 2.7 96.8 ± 6.1 0.7293 89.3 ± 5.7 91.7 ± 5.6 0.3397
CD39 16.2 ± 8.7 22.1 ± 9.4 0.0377 69.4 ± 7.6 74.0 ± 10.7 0.3064
  1. PBMC were analyzed before and after iv-SIL treatment by flow cytometry, as described in the “Methods” section, and the overall analysis of HLA-DR, CD83, CD86, ICOSL, PD-L1, HLA-G, IL-T4, and CD39 expression (%, mean SD) by mDC and pDC is presented. Italicized values denote significance